Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.35 |
| ▸ | FABP3 | P05413 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10440713 | 0.98 | ALDH1A1 (0.40) | ALDH1A1MAPK1SMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL10440712 | 0.86 | KEAP1 (0.30) | ALDH1A1MAPK1SMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL30932668 | 0.76 | ALDH1A1 (0.48) | ALDH1A1MAPK1SMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL2094993 | 0.76 | ALDH1A1 (0.48) | ALDH1A1MAPK1SMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL2092313 | 0.76 | GAA (0.38) | ALDH1A1MAPK1 | |
| SCHEMBL5775563 | 0.75 | — | — | |
| SCHEMBL5775555 | 0.75 | — | — | |
| SCHEMBL5775558 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL9088762 | 0.74 | ALDH1A1 (0.47) | ALDH1A1MAPK1SMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL8133509 | 0.73 | ALDH1A1 (0.37) | ALDH1A1MAPK1SMN1; SMN2FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080171732-A1 | New Pyridine Analogues IX 519 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1631570-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Abbott Laboratories (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004083207-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
| EP-0153580-B2 | NAPHTHYRIDINE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0387802-A2 | 5-Substituted-1,4-dihydro-4-oxonaphthyridine-3-carboxylate antibacterial agents | Bristol-Myers Squibb Company (US) | 1990-09-19 | — | — | EP | disclosed |
| EP-0153580-B1 | NAPHTHYRIDINE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 1989-01-25 | — | — | EP | disclosed |
| EP-0153580-A1 | Naphthyridine antibacterial compounds | ABBOTT LABORATORIES (US) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171732-A1 | New Pyridine Analogues IX 519 | P2RY12, P2RY11, P2RY1 | ALDH1A1 1518/4885MAPK1 979/4885SMN1; SMN2 3568/4885 |
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | ALDH1A1 292/4885MAPK1 341/4885SMN1; SMN2 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.